Glofitamab is part of Genentech's industry-leading CD20xCD3 bispecific antibody development program, which aims to address the diverse needs and preferences of people with blood cancers.
Uses
Glofitamab is a T-cell binding bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells.
